# InpharmD **Source:** https://geo.sig.ai/brands/inpharmd **Vertical:** Healthcare **Subcategory:** General **Tier:** Emerging **Website:** inpharmd.com **Last Updated:** 2026-04-14 ## Summary AI drug information platform with clinical pharmacist review for healthcare providers; $6.5M seed from 645 Ventures and YC competing with UpToDate for complex drug interaction and dosing guidance. ## Company Overview InpharmD is an Atlanta-based healthcare technology company providing AI-assisted drug information and clinical pharmacist intelligence to healthcare providers — enabling physicians, nurses, and clinical staff to get evidence-based answers to complex drug questions (drug interactions, off-label use guidance, dosing in special populations, emerging therapies) through an AI platform that combines clinical pharmacist review with database-backed pharmaceutical intelligence. Founded in 2018 and a Y Combinator W21 graduate, InpharmD raised $6.63 million total including a $6.5 million seed round in December 2023 led by 645 Ventures with participation from Qlarant Capital and Atlanta Ventures. InpharmD's platform delivers AI-generated drug information responses that are reviewed and validated by clinical pharmacists before delivery, providing a higher standard of reliability than pure AI-generated responses for clinical decision support. Healthcare providers can query drug interactions for complex polypharmacy patients, dosing guidance for renal or hepatic impairment, and evidence reviews for emerging treatments where prescribing guidance is evolving rapidly. The pharmacist-in-the-loop review model addresses the reliability requirements for clinical AI tools where incorrect information can cause patient harm. In 2025, InpharmD competes in the clinical decision support and pharmacy intelligence market with Wolters Kluwer (UpToDate, the dominant clinical reference), Elsevier (Clinical Pharmacology), IBM Watson Health (legacy), and newer AI clinical assistants (Doximity AI, Glass Health) for healthcare provider drug information. Clinical pharmacist access is increasingly limited in many hospital systems — telepharmacy and centralized pharmacy models have reduced the availability of pharmacists for individual clinician questions. InpharmD's AI-assisted pharmacist service expands access to pharmaceutical expertise. The 645 Ventures and YC backing validates the healthcare AI market opportunity. The 2025 strategy focuses on hospital system and health system enterprise deployments, expanding the AI model's pharmaceutical knowledge base, and building the formulary and insurance coverage intelligence that completes the prescribing decision context. ## Frequently Asked Questions ### What is InpharmD? InpharmD is an Atlanta-based healthcare technology company founded in 2018 that provides AI-generated drug information reviewed by clinical pharmacists. The company delivers pharmaceutical intelligence solutions to healthcare providers and participated in Y Combinator's Winter 2021 cohort. ### What products and services does InpharmD offer? InpharmD offers AI-powered drug information, clinical pharmacist reviews, pharmaceutical intelligence, a healthcare AI platform, and drug safety data. All drug information is generated by AI and reviewed by clinical pharmacists to ensure accuracy. ### Who are InpharmD's target customers? InpharmD serves healthcare providers who need access to reliable drug information and pharmaceutical intelligence for clinical decision-making. ### When was InpharmD founded? InpharmD was founded in 2018 and later participated in Y Combinator's Winter 2021 (W21) cohort. ### Where is InpharmD located? InpharmD is headquartered in Atlanta, Georgia, United States. ### How much funding has InpharmD raised? InpharmD has raised $6.63M in total funding, including a $6.5M seed round in December 2023. The seed round was led by 645 Ventures with participation from Y Combinator, Qlarant Capital, ELC, and Atlanta Ventures. ### What is InpharmD's connection to Y Combinator? InpharmD was part of Y Combinator's Winter 2021 (W21) cohort. Y Combinator also participated as an investor in the company's December 2023 seed funding round. ### What technology approach does InpharmD use? InpharmD combines artificial intelligence with clinical pharmacist expertise to generate and verify drug information. The company deployed Avesha's Elastic GPU Service to Nebius AI Cloud in July 2025 to power its AI-driven pharmaceutical intelligence platform. ### How can I get started with InpharmD or contact them? Based on the provided information, specific contact details or onboarding processes are not available. InpharmD is based in Atlanta, Georgia and serves healthcare providers. ### What are InpharmD's recent developments? InpharmD recently raised a $6.5M seed round in December 2023 led by 645 Ventures. In July 2025, the company successfully deployed Avesha's Elastic GPU Service to Nebius AI Cloud to enhance its AI-powered pharmaceutical intelligence capabilities. ## Tags healthtech, saas, north-america, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*